Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
OBJECTIVE
To compare the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone and pioglitazone.


METHODS
Retrospective cohort study.


METHODS
Ontario, Canada.


METHODS
Outpatients aged 66 years and older who were started on rosiglitazone or pioglitazone between 1 April 2002 and 31 March 2008.


METHODS
Composite of death or hospital admission for either acute myocardial infarction or heart failure. In a secondary analysis, each outcome was also examined individually.


RESULTS
39 736 patients who started on either pioglitazone or rosiglitazone were identified. During the six year study period, the composite outcome was reached in 895 (5.3%) of patients taking pioglitazone and 1563 (6.9%) of patients taking rosiglitazone. After extensive adjustment for demographic and clinical factors and drug doses, pioglitazone treated patients had a lower risk of developing the primary outcome than did patients treated with rosiglitazone (adjusted hazard ratio 0.83, 95% confidence interval 0.76 to 0.90). Secondary analyses revealed a lower risk of death (adjusted hazard ratio 0.86, 0.75 to 0.98) and heart failure (0.77, 0.69 to 0.87) with pioglitazone but no significant difference in the risk of acute myocardial infarction (0.95, 0.81 to 1.11). One additional composite outcome would be predicted to occur annually for every 93 patients treated with rosiglitazone rather than pioglitazone.


CONCLUSIONS
Among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified.
Juurlink
David N
DN
Division of Clinical Pharmacology and Toxicology, Department of Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. dnj@ices.on.ca
Gomes
Tara
T
Lipscombe
Lorraine L
LL
Austin
Peter C
PC
Hux
Janet E
JE
Mamdani
Muhammad M
MM
D000368:Aged; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced*; D000077205:Pioglitazone; D012189:Retrospective Studies; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
Diabetes Care. 2004 May;27(5):1047-53
15111519
Int J Cardiol. 2009 Jan 24;131(3):298-304
18684530
Diabet Med. 2005 Aug;22(8):986-93
16026362
JAMA. 2007 Dec 12;298(22):2634-43
18073359
Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):753-9
18613215
Arch Intern Med. 2003 Feb 24;163(4):481-6
12588209
Mayo Clin Proc. 2004 Apr;79(4):571; author reply 575-7
15065625
J Pharmacol Exp Ther. 1998 Feb;284(2):751-9
9454824
N Engl J Med. 2007 Jul 5;357(1):67-9
17551162
Clin Cardiol. 2008 Sep;31(9):397-403
18781598
Diabetes Care. 2005 Jul;28(7):1547-54
15983299
J Clin Epidemiol. 2010 Jan;63(1):2-6
19230611
N Engl J Med. 2004 Aug 5;351(6):543-51
15295047
J Am Coll Cardiol. 2005 Jun 21;45(12):1925-31
15963388
Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71
17674425
N Engl J Med. 2007 Aug 30;357(9):844-6
17687124
Diabetes Care. 1999 Apr;22(4):562-8
10189532
Am Heart J. 2002 Aug;144(2):290-6
12177647
N Engl J Med. 2007 Jul 5;357(1):28-38
17551159
Lancet. 2005 Oct 8;366(9493):1279-89
16214598
JAMA. 2007 Sep 12;298(10):1189-95
17848653
Nat Med. 2005 Aug;11(8):861-6
16007095
Lancet. 2007 Sep 29;370(9593):1129-36
17905165
Clin Ther. 2002 Mar;24(3):378-96
11952022
JAMA. 2007 Sep 12;298(10):1216-8
17848659
BMJ. 2005 Apr 23;330(7497):960-2
15845982
N Engl J Med. 2007 Jun 14;356(24):2457-71
17517853
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9406-11
15956187
Mayo Clin Proc. 2003 Sep;78(9):1088-91
12962163
N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40
17806135
Med Care. 2005 Feb;43(2):182-8
15655432
JAMA. 2007 Sep 12;298(10):1180-8
17848652
Diabet Med. 2008 Jul;25(7):871-4
18644075
Diabetes Care. 2002 Mar;25(3):512-6
11874939
N Engl J Med. 2006 Mar 30;354(13):1352-61
16510739